Autobio Diagnostics

Executive Summary

Autobio Diagnostics is a leading Chinese in-vitro diagnostics (IVD) company founded in 1993, headquartered in Zhengzhou. It develops, manufactures, and markets a comprehensive portfolio of diagnostic instruments, reagents, and solutions, with a core focus on automated immunoassay systems (AutoLumo series) and total laboratory automation (TLA). The company serves diverse therapeutic areas including infectious diseases, oncology, endocrinology, cardiovascular health, autoimmune disorders, and women's health. With over 1,000 employees and a commercial-stage status, Autobio has established a strong presence in China's IVD market and is expanding its global footprint. Its integrated product offerings and emphasis on automation position it to capitalize on the growing demand for efficient, high-throughput diagnostics in both hospital and reference laboratory settings.

Upcoming Catalysts (preview)

• Q3 2026Approval of next-generation AutoLumo flagship immunoassay analyzer75% success
• Q4 2026Expansion into emerging markets (e.g., Southeast Asia, Africa) via new distribution agreements60% success
• TBDLaunch of new high-sensitivity cardiac troponin assay for early detection of myocardial infarction80% success